Completed

Zinc Acetate for Copper Regulation in Wilson Disease

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

zinc acetate

Drug
Who is being recruted

Basal Ganglia Diseases+19

+ Brain Diseases

+ Brain Diseases, Metabolic

See all eligibility criteria
How is the trial designed

Treatment Study

Phase 4
Interventional
Study Start: October 1993
See protocol details

Summary

Principal SponsorNational Center for Research Resources (NCRR)
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Study start date: October 1, 1993

Actual date on which the first participant was enrolled.

PROTOCOL OUTLINE: Patients receive copper regulation therapy with zinc acetate: an existing cohort on maintenance therapy will be followed for long-term data collection; presymptomatic patients are treated prophylactically; and pregnant patients are evaluated for fetal outcome. All patients are evaluated for copper balance, clinical control, and toxicity.

NCT00004338
Principal SponsorNational Center for Research Resources (NCRR)
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

300 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Basal Ganglia DiseasesBrain DiseasesBrain Diseases, MetabolicCentral Nervous System DiseasesDigestive System DiseasesLiver DiseasesMetabolic DiseasesMetal Metabolism, Inborn ErrorsMovement DisordersCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesNervous System DiseasesNutritional and Metabolic DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsNeurodegenerative DiseasesHeredodegenerative Disorders, Nervous SystemBrain Diseases, Metabolic, InbornDisease AttributesGenetic Diseases, InbornHepatolenticular DegenerationMetabolism, Inborn ErrorsRare Diseases

Criteria

PROTOCOL ENTRY CRITERIA: Wilson disease Presymptomatic, pregnant, and children 16 years or younger patients eligible Patient age: Any age, including children

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

University of Michigan Health Systems

Ann Arbor, United StatesOpen University of Michigan Health Systems in Google Maps
CompletedOne Study Center